HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

ALIOF: ACTELION LTD - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

ACTELION LTD (OTC)
ALIOF 39.10 -0.25 (-0.64%) Vol.  300 10:55 ET

Zacks Rank: 4 - Sell

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 39.10 - 39.10
52wk Low - High 32.15 - 57.75
Avg Volume 122
Industry MED-BIOMED/GENE
Market Cap 5.13 B
Div - Yield 0.00 - 0.00
PE (forward) 12.35
PEG Ratio N/A
Current Year Est. 3.18
EPS Last Year 3.09
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
4 - Sell
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
ACTELION LTD ALIOF 4
ACADIA PHARMA ACAD 1
YM BIOSCI INC YMI 1
ARENA PHARMA ARNA 1
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.00
ABR (Last Week) 1.00
# of Recs in ABR 2
Average Target Price 57.76
Rank in Industry 1 out of 179
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate ALIOF?
Buy
Sell
Find out what the Zacks Community
thinks of ALIOF at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR ALIOF
Zacks Blog: Actelion Tops, Currency Plays Spoil
Oct 25, 2011
Zacks Blog: InterMune's Esbriet to Launch in EU
Sep 13, 2011
Zacks Blog: Currency Mars Actelion 2Q
Jul 22, 2011
Zacks Blog: Actelion Sets $577M Aside
Jul 05, 2011
Zacks Blog: Actelion Beats Estimates
Apr 20, 2011
Zacks Blog: Label Change for GILD Drug?
Mar 08, 2011
Zacks Blog: Top and Bottom Grow at ALIOF
Feb 22, 2011
More Zacks Commentary
NEWS
Actelion to present at the 30th Annual J.P. Morgan Healthcare Conference - Getting ready for Actelion's next growth phase
Jan 09, 2012
Actelion to present at the 30th Annual J.P. Morgan Healthcare Conference - Getting ready for Actelion's next growth phase - Story Title - Comtex
Jan 09, 2012
Amendment of judgment of the court of first instance in litigation with Actelion Ltd. of Switzerland
Nov 22, 2011
Amendment of judgment of the court of first instance in litigation with Actelion Ltd. of Switzerland - Story Title - Comtex
Nov 22, 2011
Judgment in litigation between Actelion and Asahi Kasei is issued by Californian Court - Original jury verdict reduced by almost USD 170 million - Actelion set to appeal the entire verdict
Nov 21, 2011
Judgment in litigation between Actelion and Asahi Kasei is issued by Californian Court - Original jury verdict reduced by almost USD 170 million - Actelion set to appeal the entire verdict - Story Title - Comtex
Nov 21, 2011
Actelion provides update on judgment in Asahi Kasei litigation
Oct 24, 2011
Actelion provides update on judgment in Asahi Kasei litigation - Story Title - Comtex
Oct 24, 2011
More News
EARNINGS ESTIMATES
  This Quarter
12/2011
Next Quarter
03/2012
This Year
12/2011
Next Year
12/2012
Average Estimate 0.84 N/A 2.72 3.18
Number of Estimates 1 0 2 2
Low Estimates 0.84 N/A 2.42 3.12
High Estimate 0.84 N/A 3.01 3.25
Year Ago EPS 0.26 1.34 3.09 2.72
EPS Growth 223.08% N/A% -12.14% 17.31%

More Estimates

COMPANY DESCRIPTION
Actelion Limited is an independent, profitable, biopharmaceutical company discovering, developing and marketing drugs for high unmet medical needs.

Full Company Report
FINANCIALS
EPS TTM 3.09
Sales 1853.74
Net Income -183.47
Price/Earnings 12.73
Price/Book 2.84
Price/Cash Flow 11.54
Price/Sales 2.55


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research